KR101599087B1 - Cav2.2 칼슘 채널 모듈레이터로서 사용되는 피페라진 유도체 - Google Patents

Cav2.2 칼슘 채널 모듈레이터로서 사용되는 피페라진 유도체 Download PDF

Info

Publication number
KR101599087B1
KR101599087B1 KR1020117001109A KR20117001109A KR101599087B1 KR 101599087 B1 KR101599087 B1 KR 101599087B1 KR 1020117001109 A KR1020117001109 A KR 1020117001109A KR 20117001109 A KR20117001109 A KR 20117001109A KR 101599087 B1 KR101599087 B1 KR 101599087B1
Authority
KR
South Korea
Prior art keywords
methyl
mmol
pain
sulfonyl
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117001109A
Other languages
English (en)
Korean (ko)
Other versions
KR20110031199A (ko
Inventor
파울 존 베스위크
알리스터 캄프벨
앤드류 피터 크리드랜드
로버트 제임스 글리브
자그 파울 헤에르
네빌레 허버트 니콜손
리 윌리암 페이지
사디에 빌레
Original Assignee
컨버전스 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컨버전스 파마슈티컬즈 리미티드 filed Critical 컨버전스 파마슈티컬즈 리미티드
Publication of KR20110031199A publication Critical patent/KR20110031199A/ko
Application granted granted Critical
Publication of KR101599087B1 publication Critical patent/KR101599087B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117001109A 2008-07-17 2009-07-15 Cav2.2 칼슘 채널 모듈레이터로서 사용되는 피페라진 유도체 Expired - Fee Related KR101599087B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0813142.7 2008-07-17
GBGB0813142.7A GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds

Publications (2)

Publication Number Publication Date
KR20110031199A KR20110031199A (ko) 2011-03-24
KR101599087B1 true KR101599087B1 (ko) 2016-03-02

Family

ID=39737239

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117001109A Expired - Fee Related KR101599087B1 (ko) 2008-07-17 2009-07-15 Cav2.2 칼슘 채널 모듈레이터로서 사용되는 피페라진 유도체

Country Status (19)

Country Link
US (3) US8530478B2 (cg-RX-API-DMAC7.html)
EP (2) EP2300432B1 (cg-RX-API-DMAC7.html)
JP (2) JP5543966B2 (cg-RX-API-DMAC7.html)
KR (1) KR101599087B1 (cg-RX-API-DMAC7.html)
CN (1) CN102099337B (cg-RX-API-DMAC7.html)
AR (1) AR072809A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009272762B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916622A2 (cg-RX-API-DMAC7.html)
CA (1) CA2730471C (cg-RX-API-DMAC7.html)
EA (1) EA018621B1 (cg-RX-API-DMAC7.html)
ES (2) ES2396960T3 (cg-RX-API-DMAC7.html)
GB (1) GB0813142D0 (cg-RX-API-DMAC7.html)
IL (1) IL210446A (cg-RX-API-DMAC7.html)
MX (1) MX2011000600A (cg-RX-API-DMAC7.html)
PL (1) PL2300432T3 (cg-RX-API-DMAC7.html)
TW (1) TW201016677A (cg-RX-API-DMAC7.html)
UY (1) UY31990A (cg-RX-API-DMAC7.html)
WO (2) WO2010007073A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100014B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB201000685D0 (en) * 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
US8933132B2 (en) * 2011-01-19 2015-01-13 Convergence Pharmaceuticals Limited Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
CN103781759B (zh) 2011-06-27 2016-01-13 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
EA032638B1 (ru) * 2014-04-14 2019-06-28 Грюненталь Гмбх Арилзамещенные гетероциклилсульфоны
US9879000B2 (en) * 2014-04-14 2018-01-30 Grünenthal GmbH Heteroaryl substituted heterocyclyl sulfones
GB201516183D0 (en) * 2015-09-14 2015-10-28 Calchan Ltd Novel pharmaceutical composition
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
EP3615521A4 (en) * 2017-04-26 2021-02-17 Cavion, Inc. METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
CN118085389B (zh) * 2024-03-11 2024-11-05 伟建实业(苏州)有限公司 一种环保型抗菌海绵及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024284A2 (en) 2006-08-21 2008-02-28 Merck & Co., Inc. Sulfonylated piperazines as cannabinoid-1 receptor modulators

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006371A1 (fr) 1987-02-13 1988-08-25 Mitsubishi Denki Kabushiki Kaisha Demarreur/chargeur pour moteurs
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5498711A (en) 1993-02-03 1996-03-12 Thiokol Corporation Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
EP0820452B1 (en) 1995-04-07 2003-06-04 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
FR2744450A1 (fr) 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
GB9623283D0 (en) 1996-11-08 1997-01-08 Zeneca Ltd Heterocyclic derivatives
US6359134B1 (en) 1997-05-30 2002-03-19 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB9927844D0 (en) 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2001076693A1 (en) 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2812198B1 (fr) 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
JP4365102B2 (ja) 2001-04-26 2009-11-18 コーロン ライフ サイエンス インク 新規なスルホンアミド誘導体、その中間体化合物、及びその製造方法、並びにスルホンアミド誘導体を含む薬剤学的組成物
DE10155684A1 (de) 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
RU2323935C2 (ru) 2002-04-18 2008-05-10 Шеринг Корпорейшн Производные бензимидазола, их применение и фармацевтическая композиция на их основе, обладающая свойствами антагониста рецептора гистамина h3
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
DE10319435B4 (de) * 2003-04-25 2018-07-26 Whitecryption Corporation Verfahren zur Verarbeitung von Daten zum Schutz eines Softwareprogramms vor Rekonstruktion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2559285A1 (en) 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
DE102004035672A1 (de) 2004-07-22 2006-03-30 Windmöller & Hölscher Kg Verkürzte Stapelbildung
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
DE102004054053A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2632030A1 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
AU2006331850A1 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
EP1965799A2 (en) 2005-12-22 2008-09-10 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
WO2007103456A2 (en) 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
NZ578063A (en) 2006-12-18 2011-09-30 7Tm Pharma As Cannabinoid CB1 receptor modulators
US7648979B2 (en) 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
JP5380435B2 (ja) 2007-05-31 2014-01-08 ユーロ−セルティーク ソシエテ アノニム アミド化合物およびその使用
EP2164325B1 (en) 2007-05-31 2013-04-24 Shionogi&Co., Ltd. Oxyimino compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
ES2428326T3 (es) 2007-10-04 2013-11-07 Merck Sharp & Dohme Corp. Derivados de aril sulfona sustituida como bloqueadores de canales de calcio
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024284A2 (en) 2006-08-21 2008-02-28 Merck & Co., Inc. Sulfonylated piperazines as cannabinoid-1 receptor modulators

Also Published As

Publication number Publication date
EP2300432B1 (en) 2012-10-03
BRPI0916622A2 (pt) 2019-04-09
MX2011000600A (es) 2011-05-24
EP2346828B1 (en) 2012-10-03
GB0813142D0 (en) 2008-08-27
WO2010007073A1 (en) 2010-01-21
EP2346828A1 (en) 2011-07-27
ES2396960T3 (es) 2013-03-01
JP5543966B2 (ja) 2014-07-09
US20110130379A1 (en) 2011-06-02
ZA201100014B (en) 2011-09-28
AU2009272762A1 (en) 2010-01-21
ES2396962T3 (es) 2013-03-01
CA2730471A1 (en) 2010-01-21
EP2300432A1 (en) 2011-03-30
TW201016677A (en) 2010-05-01
PL2300432T3 (pl) 2013-03-29
US20120302746A1 (en) 2012-11-29
IL210446A (en) 2014-01-30
WO2010007072A1 (en) 2010-01-21
JP2011528020A (ja) 2011-11-10
CA2730471C (en) 2016-12-06
KR20110031199A (ko) 2011-03-24
JP5688850B2 (ja) 2015-03-25
US8288388B2 (en) 2012-10-16
CN102099337B (zh) 2013-08-21
AU2009272762B2 (en) 2013-08-15
US8530478B2 (en) 2013-09-10
CN102099337A (zh) 2011-06-15
US20100022555A1 (en) 2010-01-28
UY31990A (es) 2010-01-05
AR072809A1 (es) 2010-09-22
EA201170209A1 (ru) 2011-08-30
JP2011528019A (ja) 2011-11-10
EA018621B1 (ru) 2013-09-30
IL210446A0 (en) 2011-03-31
US8536183B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
EP2300432B1 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
EP3191472B1 (en) Compounds and compositions as raf kinase inhibitors
EP3414227B1 (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CA3128062A1 (en) Benzopyridone heterocyclic compound and use thereof
CN110730777A (zh) 作为atf4通路抑制剂的化学化合物
WO2019173182A1 (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
PH12014501162B1 (en) Aryl dihydropyridinone and piperidinone as mgat2 inhibitors
TW201734021A (zh) 布魯頓氏(bruton)酪胺酸激酶抑制劑及其使用方法
WO2018227065A1 (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
AU2024277772A1 (en) Aromatic amides and conjugates thereof as binders to tead
AU2019424628B2 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
WO2010007074A1 (en) Pyrazolo [1, 5-a] pyrimidine derivatives
AU2013242858B2 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
HK40071411A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
HK40035056B (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
HK40035056A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
BR112017002053B1 (pt) Composto de acordo com a fórmula (xi) e uso de um composto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190225